Diabetes pipeline cannot reverse cardiovascular and metabolic market decline, says Datamonitor

Strong diabetes growth will not be enough to stop the cardiovascular and metabolic market from declining, according to independent market analyst Datamonitor.

Datamonitor forecasts that the cardiovascular and metabolic market across the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK) will peak in 2011 and then begin to decline, with total sales falling from $105 billion in 2009 to $101 billion in 2019. In contrast, the volume of sales will continue to increase, driven by aging populations and higher rates of obesity.

Christine Henry, health care analyst at Datamonitor, comments: “The proportion of the market composed of branded therapies is forecast to fall and by 2019, generics and biosimilars will contribute 68% of volume sales across the seven major markets, and 28% of sales.”